These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 15476151)

  • 21. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
    Valat JP; Deray G; Héloire F
    Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical profiles of celecoxib and rofecoxib in the rheumatic diseases.
    Gibofsky A
    J Hypertens Suppl; 2002 Sep; 20(6):S25-30. PubMed ID: 12683424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure in Native Americans switched from celecoxib to rofecoxib.
    Fredy J; Diggins DA; Morrill GB
    Ann Pharmacother; 2005 May; 39(5):797-802. PubMed ID: 15797981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib and rofecoxib. The role of COX-2 inhibitors in dental practice.
    Moore PA; Hersh EV
    J Am Dent Assoc; 2001 Apr; 132(4):451-6. PubMed ID: 11315375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
    Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E; Hunsche E; Toubouti Y; Chabot I
    Arthritis Rheum; 2006 Feb; 55(1):27-34. PubMed ID: 16463408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for post-operative pain.
    Rømsing J; Møiniche S
    Acta Anaesthesiol Scand; 2004 May; 48(5):525-46. PubMed ID: 15101847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs.
    Zhao SZ; Wentworth C; Burke TA; Makuch RW
    Pharmacoepidemiol Drug Saf; 2004 May; 13(5):277-87. PubMed ID: 15133778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
    Whelton A; White WB; Bello AE; Puma JA; Fort JG;
    Am J Cardiol; 2002 Nov; 90(9):959-63. PubMed ID: 12398962
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs.
    Phelan KM; Mosholder AD; Lu S
    J Clin Psychiatry; 2003 Nov; 64(11):1328-34. PubMed ID: 14658947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient characteristics associated with outpatient prescriptions for nabumetone and oxaprozin versus celecoxib and rofecoxib.
    Brinker A; Nourjah P
    Am J Health Syst Pharm; 2005 Apr; 62(7):739-43. PubMed ID: 15790802
    [No Abstract]   [Full Text] [Related]  

  • 33. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction.
    Brophy JM; Lévesque LE; Zhang B
    Heart; 2007 Feb; 93(2):189-94. PubMed ID: 16849374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery.
    Reuben SS; Connelly NR
    Anesth Analg; 2000 Nov; 91(5):1221-5. PubMed ID: 11049912
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
    Zembowicz A; Mastalerz L; Setkowicz M; Radziszewski W; Szczeklik A
    Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adoption of celecoxib and rofecoxib: a nationwide database study.
    Helin-Salmivaara A; Huupponen R; Virtanen A; Klaukka T
    J Clin Pharm Ther; 2005 Apr; 30(2):145-52. PubMed ID: 15811167
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis.
    Schnitzer TJ; Kong SX; Mitchell JH; Mavros P; Watson DJ; Pellissier JM; Straus WL
    Clin Ther; 2003 Dec; 25(12):3162-72. PubMed ID: 14749154
    [TBL] [Abstract][Full Text] [Related]  

  • 39. COX-2 inhibition and thrombotic tendency: a need for surveillance.
    Cleland LG; James MJ; Stamp LK; Penglis PS
    Med J Aust; 2001 Aug; 175(4):214-7. PubMed ID: 11587283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs.
    Mardini IA; FitzGerald GA
    Mol Interv; 2001 Apr; 1(1):30-8. PubMed ID: 14993336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.